The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy

International Journal of Gynecological Cancer

Volumn 9, Issue 3, 1999, Pages 198-205

  De Jonge, E T M ^a,d   Viljoen, E ^b   Lindeque, B G ^a   Amant, F ^a   Nesland, J M ^c   Holm, R ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF OSLO   (Norway)

^d Dept of Obstetrics and Gynaecology ^*  (South Africa)

Author keywords

Cervix neoplasms; Prognostic factors; Radical hysterectomy; Survival

Indexed keywords

CATHEPSIN D; PROTEIN MDM2; PROTEIN P53; RECEPTOR PROTEIN; TYROSINE KINASE RECEPTOR;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADICAL HYSTERECTOMY; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 0033047344     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99019.x     Document Type: Article

References (60)

1. Curtin JP. Radical hysterectomy - the treatment of choice for early-stage cervical carcinoma. Gynecol Oncol 1996; 62: 137-8.
2. Shingleton HM, Orr JW Jr. Primary surgical treatment of invasive cancer. In: Shingleton HM, Orr JW Jr, eds. Cancer of the cervix. JB Lippincott Company: Philadelphia 1995, 123-154.
3. Landoni F, Maneo A, Colombo A et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-40.
4. Finan MA, DeCesare S, Fiorica JV et al. Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival? Gynecol Oncol 1996; 62: 139-47.
5. Cox DR. Regression models and life tables. J R Stat Soc; 172: 34:187-202.
6. Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. Stat Med 1989; 8: 539-50.
7. Sevin BU, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE. Surgically defined prognostic parameters in patients with early cervical carcinoma: a multivariate survival tree analysis. Cancer 1996; 78: 1438-46.
8. Fox H. Clinical value of new techniques of gynecological tumor assessment. Int J Gynecol Cancer 1997; 7: 337-49.
9. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636-41.
10. Metha P. Potential role for platelets in the pathogenesis of tumour metastasis. Blood 1984; 63: 55-63.
11. Gasic GL, Gasic TB, Stewart CC. Role of plasma, platelets, and endothelial cells in tumour metastasis. Cancer Metastasis Rev 1984; 3: 99-116.
12. Hernandez E, Lavine M, Dunton CJ et al. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-7.
13. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994; 83: 445-8.
14. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994; 74: 90-2.
15. Hernandez E, Heller PB, Whitney C, Diana K, Delgado G. Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (A Gynecologic Oncology Group study). Gynecol Oncol 1994; 55: 328-32.
16. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumour-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-22.
17. Helland Å, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993; 171: 105-14.
18. Schneider J, Rubio MP, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry. Eur J Cancer 1994; 30: 504-8.
19. Ikenberg H, Matthay K, Schmitt B et al. p53 mutation and mdm2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 1995; 76: 57-66.
20. Benjamin I, Saigo P, Finstad C et al. Expression and mutational analysis of p53 in stage IB and IIA cervical cancers. Am J Obstet Gynecol 1996; 175: 1266-71.
21. Oka K, Nakano T, Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993; 72: 160-4.
22. Gitsch G, Kainz C, Joura E, Breitenecker G. Mutant p53 product in patients with stage III cervical cancer. Anticancer Res 1992; 12: 2241-2.
23. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol Oncol 1995; 57: 212-4.
24. Ebara T, Mitsuhashi N, Saito Y et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol Oncol 1996; 63: 216-8.
25. Helland A, Holm R, Kristensen G et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993; 171: 105-14.
26. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
27. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
28. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993; 4: 19-26.
29. Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992; 45: 594-6.
30. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46: 149-53.
31. Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 664-71.
32. Kihana T, Tsuda H, Teshima S et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 148-53.
33. Mandai M, Konishi I, Koshiyama M et al. Altered expression of nm23-H1 and c-erbB-2 proteins have a prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995; 75: 2523-9.
34. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79: 513-20.
35. Costa MJ, Walls J, Trelford JD. c-erbB-2 Oncoprotein overexpression uterine cervix carcinoma with glandular differentiation - a frequent event but not an independent prognostic marker because it occurs late in the disease. Am J Clin Pathol 1995; 104:634-42.
36. Kristensen GB, Holm R, Abeler VM, Tropé CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78: 433-40.
37. Wong YF, Chung TK, Cheung TH et al. HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. J Obstet Gynaecol Res 1996; 22: 171-5.
38. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990; 16: 3-13.
39. Scambia G, Panici PB, Ferrandina G et al. Significance of cathepsin D expression in uterine tumors. Eur J Cancer 1995; 31A: 1449-54.
40. FIGO. Changes to the 1985 FIGO report on the result of treatment in gynecological cancer. Int J Gynecol Obstet 1987; 25: 87-8.
41. Cattoretti G, Becker HG, Key G, Duchrow M, Schluter C, Galle J. Monoclonal antibodies against recombinants part of Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
42. Mantel N. Evaluation of survival data and two new rank order statistic arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
43. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995; 58: 157-8.
44. Delgado G, Bundy B, Fowler WC et al. A prospective surgical-pathological study of Stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 35: 314-20.
45. Friedberg V. Operative therapy for stage IIB cervical cancer. Baillieres Clin Obstet Gynaecol 1988; 2: 973-80.
46. Sevin BU, Nadji M, Lampe B et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995; 76: 1978-86.
47. Shingleton HM, Bell MC, Fremgen A et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 1995; 76: 1948-55.
48. Look KY, Brunetto VL, Clarke-Pearson DL et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 63: 304-11.
49. Pickel H, Haas J, Lahousen M. Prognostic factors in cervical cancer on the basis of morphometric evaluation. Ballières Clin Obstet Gynaecol 1988; 2: 805-15.
50. Buckley SL, Tritz DM, Van Le L et al. Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynecol Oncol 1996; 63: 4-9.
51. Noguchi H, Shiozawa K, Tsukamoto T, Tsukahara Y, Iwai S, Fukuta T. The postoperative classification for uterine cervical cancer and its clinical evaluation. Gynecol Oncol 1983; 16: 219-31.
52. Boyce J, Fruchter RG, Nicastri AD et al. Vascular invasion in stage I carcinoma of the cervix. Cancer 1984; 53: 1175-80.
53. Burke TW, Hoskins WJ, Heller PB, Bibro MC, Weiser EB, Park PC. Prognostic factors associated with radical hysterectomy failure. Gynecol Oncol 1987; 26: 153-9.
54. Delgado G, Bundy B, Zaino R, Sevin B, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38: 352-7.
55. Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF. Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol 1997; 66: 31-5.
56. Morrow CP. Panel Report: Is pelvic radiation beneficial in the postoperative management of stage IB squamous cell carcinoma of the cervix with pelvic node metastases treated by radical hysterectomy and pelvic lymphadenectomy? Gynecol Oncol 1980; 10: 105-10.
57. Shingleton HM, Orr JW Jr. Other treatments. In: Shingleton HM, Orr JW Jr, eds. Cancer of the cervix. JB Lippincott Company: Philadelphia 1995, 123-154.
58. Himmelmann A, Holmberg E, Jansson I, Odén A, Skogsberg K. The effect of postoperative external radiotherapy on cervical carcinoma stage Ib and IIa. Gynecol Oncol 1985; 22: 73-84.
59. Vavra N, Sevelda P, Seifert M, Timar J, Kudielka I, Kucera H. The value of adjuvant irradiation in lymphatic vessel invasion in patients with cervical carcinoma in histopathological stage Ib and with negative lymph nodes. Strahlenter Onkol 1992; 168: 524-7.
60. de Jonge ETM, Makin JD, Lindeque BG, Brune P, Amant F. Ethnic differences in thrombocytosis in patients with cervical cancer. Int J Gynecol Cancer 1998; 8: 189-92.